Bioasis Technologies (BTI) Stock Price, News & Analysis

Company Overview

Bioasis Technologies Inc., a development stage biopharmaceutical company, engages in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. It is developing xB3, a platform technology for the transport of therapeutic agents across the blood-brain barrier (BBB); and the treatment of central nervous system disorders (CNS), including brain cancers, and metabolic and neurodegenerative diseases. The company's in-house development programs develop symptomatic and disease-modifying treatments for brain metastases (xB3-001), glioblastoma (xB3-002), and neurodegenerative diseases (xB3-007). It has research collaborations with Aposense Limited to focus on the delivery of siRNA therapeutics for CNS disorders; Oxyrane UK Ltd. to focus on combining xB3 technology and Oxyrane's OxyCAT platform to deliver an undisclosed enhanced enzyme replacement therapy into the brain; and Janssen Biotech, Inc. to research, develop, and commercialize novel products based on Bioasis' xB3 platform. The company also has a research collaboration and license agreement with Neuramedy Co Ltd. to research, develop, and commercialize an xB3TM version of its antibody, Tomaralimab. Bioasis Technologies Inc. was incorporated in 2006 and is headquartered in New Haven, Connecticut.

Key Stats

• Today's Range: C$0.01 to C$0.01
• 50-Day Range: C$0.01 to C$0.01
• 52-Week Range: C$0.01 to C$0.03
• Volume: 5,250 shs
• Average Volume: 73,137 shs
• Market Capitalization: C$397,050.00
• P/E Ratio: N/A
• Dividend Yield: 40,400.00%
• Price Target: N/A
• Consensus Rating: N/A

BTI Stock Analysis - Frequently Asked Questions

How have BTI shares performed this year?

Bioasis Technologies' stock was trading at C$0.01 at the start of the year. Since then, BTI stock has increased by 0.0% and is now trading at C$0.01.
View the best growth stocks for 2024 here.

How do I buy shares of Bioasis Technologies?

Shares of BTI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Bioasis Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioasis Technologies investors own include Achaogen (AKAO), Biora Therapeutics (BIOR), Bristol-Myers Squibb (BMY), Novavax (NVAX), Ocugen (OCGN), Pfizer (PFE) and

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Tobacco Products
• Current Symbol: CVE:BTI
• CUSIP: N/A
• CIK: N/A
• Web: www.bioasis.ca
• Phone: +1-604-2957014
• Fax: N/A
• Employees: 52,000
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-2,880,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -80.58%

Debt

• Debt-to-Equity Ratio: 27.88
• Current Ratio: 0.11
• Quick Ratio: 0.17

Sales & Book Value

• Annual Sales: C$158,165.00
• Price / Sales: 2.51
• Cash Flow: C$0.00 per share
• Price / Cash Flow: 13.57
• Book Value: C($0.03) per share
• Price / Book: -0.17

Miscellaneous

• Outstanding Shares: 79,410,000
• Free Float: N/A
• Market Cap: C$397,050.00
• Optionable: Not Optionable
• Beta: 0.45